BIOGEN IDEC AND ELAN ANNOUNCE AVAILABILITY OF TYSABRI FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS

Biogen Idec and Elan Corporation, plc announced the commercial availability of TYSABRI (natalizumab) for the treatment of relapsing forms of multiple sclerosis (MS) in the U.S. As previously announced, the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for the reintroduction of TYSABRI as a monotherapy treatment for relapsing forms of MS to slow the progression of disability and reduce the frequency of clinical relapses.

Yahoo Finance (http://biz.yahoo.com/bw/060724/20060723005014.html?.v=1)